Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is an autoimmune disorder that primarily affects the joints, causing inflammation, pain, and stiffness, often leading to joint damage over time.
Rheumatoid Arthritis: LY3871801 Study
We are testing a new medication, LY3871801, for adults with moderately-to-severely active rheumatoid arthritis. The study aims to see if it can reduce disease activity better than a placebo.
3-6 monthsEfficacy phase (II)Cost ReimbursementPartially RemoteInvestigational MedicinesOralInternal MedicineRheumatology
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Do you have a diagnosis of adult onset rheumatoid arthritis for at least 3 months?
- Have you had cancer in the last 5 years, except for some types of skin cancer or cervical cancer?
- Have you had any serious infections in the last 3 months?
- Do you have HIV?
- Do you have a current hepatitis virus B or C infection?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Ly3871801
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Medical Plus s.r.o.
Uherské Hradiště, Czechia
Ass Hospitaliere Protestante De Lyon
Rhumatologie
Caluire-et-Cuire, France
Centre Hospitalier Universitaire De Reims
Rhumatologie
Cormontreuil, France
Sponsor: Eli Lilly & Co.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.